Banu K. Arun MD

Oncology•Houston, TX

Breast Cancer, Cancer Genetics/Cancer Risk Assessment, Hematologic Oncology

Professor, Oncology, University of Texas MD Anderson Cancer Center at Houston

Join to View Full Profile

1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161
Fax+1 713-563-0910

Education & Training

MedStar Health Georgetown UniversityFellowship, Hematology and Medical Oncology, 1994 - 1997
Istanbul University FomClass of 1989

Certifications & Licensure

FL State Medical License 2021 - Present
AZ State Medical License 2023 - 2026
GA State Medical License 2023 - 2026
OK State Medical License 2020 - 2026
LA State Medical License 2023 - 2025
MS State Medical License 2023 - 2025
TN State Medical License 2023 - 2025
TX State Medical License 1998 - 2025
WA State Medical License 2023 - 2025
AL State Medical License 1997 - 2011
American Board of Internal Medicine Medical Oncology
Join now to see all

Awards, Honors, & Recognition

US Top 27 Breast Oncologist Forbes, 2017
America's Top Doctors Castle Connolly, 2009-2014
Top Doctors:SE Texas Castle Connolly, 2013
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Join now to see all

Clinical Trials

Tipifarnib and Gemcitabine Hydrochloride in Treating Women With Metastatic Breast Cancer Start of enrollment: 2005 Sep 01
Completed
Phase 1, Phase 2
Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer Start of enrollment: 2003 Oct 03
Completed
Phase 2
A Phase I Prevention Study of Atorvastatin in Women at Increased Risk for Breast Cancer Start of enrollment: 2008 Mar 01
Completed
Phase 1
A Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer Start of enrollment: 2012 Jan 01
Unknown status
Phase 2
Evaluation of Antiproliferative Effects of Arimidex in Ductal Lavage Fluid in Patients With Breast Cancer Start of enrollment: 2002 Nov 01
Completed
Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer Start of enrollment: 2014 Jan 21
COMPLETED
PHASE2
A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer Start of enrollment: 2012 Jun 13
Completed
Phase 2
Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast Start of enrollment: 2018 Jan 30
Completed
Phase 2
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer Start of enrollment: 2020 Jul 28
RECRUITING
PHASE2
Willingness to Participate in a Trial Comparing Standard Genetic Counseling Versus Personalized Genetic Counseling Start of enrollment: 2022 Nov 03
RECRUITING
Roles: Principal Investigator, Contact
Connecting Black Families in Houston, Texas to Hereditary Cancer Genetic Counseling, Genetic Testing, and Cascade Testing by Using a Simple Genetic Risk Screening Tool and Telegenetics Start of enrollment: 2022 Nov 23
RECRUITING
NA
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Skin cancer risk in patients withmutations.
Lucy J Navsaria, Allen M Haas, Jessica L Corredor, Banu K Arun, Sharon H Giordano
JAAD International. 2024-12-01
1 citations
What do cancer genetic providers want us to know about variant reclassification and recontact that we are not asking? A thematic analysis of open-ended survey responses.
Kerri Brown, Marisel Ponton, Elenita Davidson, Banu Arun, Robert J Volk
Cancer. 2024-11-15
6 citations
BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing.
Banu Arun, Fergus J Couch, Jean Abraham, Nadine Tung, Peter A Fasching
British Journal of Cancer. 2024-11-01

Journal Articles

Functional Mechanisms Underlying Pleiotropic Risk Alleles at the 19p13.1 Breast–Ovarian Cancer Susceptibility Locus
Susan M Domchek, Beth Y Karlan, Katherine L Nathanson, Kenneth Offit, Banu K Arun, Andrew Berchuck, Patricia A Ganz, Douglas A Levine, Nature

Lectures

Evaluation for Genetic Risk of Breast Cancer in Mammography Centers
ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019
Non-BRCA hereditary gene mutations and breast cancer phenotype: An ISC-RAM Consortia study.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

NCCN Issues Updated Guidance on Genetic Testing for Several CancersNovember 25th, 2024
MD Anderson Research Highlights for August 25, 2021August 25th, 2021
Clinical Challenge: BRCA-Mutant Triple-Negative Breast CancerJune 8th, 2021
Join now to see all

Grant Support

Biomarker Modulation/Cox-2 Inhibitor/Breast CancerNational Cancer Institute2002–2003
An Exploratory Study To Identify Potential Surrogate ENDDivision Of Cancer Prevention And Control1999

Banu K. Arun MD

Dr. Arun is on Doximity

Education & Training

Certifications & Licensure

Awards, Honors, & Recognition

Clinical Trials

Publications & Presentations

Press Mentions

Grant Support

Viewing the full profile is available to verified healthcare professionals only.